In addition, after systemic intravenous delivery of cRGD-siEGFR, we showed that down-regulation of EGFR in mouse tumors could substantially slow tumor growth, and low toxicity or innate immune response was induced in vivo. This evidence concerns the gene EGFR and neoplasm.